Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma

Journal of Urology

Volumn 171, Issue 5, 2004, Pages 1806-1809

  Kang, David E ^a,b   White Jr , Richard L ^a   Zuger, James H ^a   Sasser, Howell C ^a   Teigland, Chris M ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Carcinoma, renal cell; Fluorodeoxyglucose F 18; Tomography, emission computed

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETROPERITONEAL TUMOR; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 5544226307     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000120241.50061.e4     Document Type: Article

References (15)

1. Scott, W. J., Schwabe, J. L., Gupta, N. C., Dewan, N. A., Reeb, S. D. and Sugimoto, J. T.: Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F] fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg, 58: 698, 1994
2. Ballet, J. W., Abemayor, E., Jabour, B. A., Hawkins, R. A., Ho, C. and Ward, P. H.: Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope, 102: 281, 1992
3. Schiepers, C., Penninckx, F., De Vadder, N., Merckx, E., Mortelmans, L., Bormans, G. et al: Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol, 21: 517, 1995
4. Avril, N., Dose, J., Janicke, F., Ziegler, S., Romer, W., Weber, W. et al: Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst, 88: 1204, 1996
5. Wahl, R. L., Harney, J., Hutchins, G. and Grossman, H. B.: Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol, 146: 1470, 1991
6. Ramdave, S., Thomas, G. W., Berlangieri, S. U., Bolton, D. M., Davis, I., Danguy, H. T. et al: Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol, 166: 825, 2001
7. Goldberg, M. A., Mayo-Smith, W. W., Papanicolaou, N., Fischman, A. J. and Lee, M. J.: FDG PET characterization of renal masses: preliminary experience. Clin Radiol, 52: 510, 1997
8. Bachor, R., Kotzerke, J., Gottfried, H. W., Brandle, E., Reske, S. N. and Hautmann, R.: Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A, 35: 146, 1996
9. Miyauchi, T., Brown, R. S. and Grossman, H. B.: Correlation between visualization of primary renal cancer by FDG-PET and histopathological findings. Abstract 245. Presented at Forty-third Annual Meeting of the Society of Nuclear Medicine, Denver, Colorado, June 3-5, 1996
10. Miyakita, H., Tokunaga, M., Onda, H., Usui, Y., Kinoshita, H., Kawamura, N. et al: Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol, 9: 15, 2002
11. Montravers, F., Grahek, D., Kerrou, K., Younsi, N., Doublet, J. D., Gattegno, B. et al: Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med, 41: 78, 2000
12. Montravers, F., Rousseau, C., Doublet, J. D., Gattengo, B., Allard, S., Fouret, P. et al: In vivo inaccessibility of somatostatin receptors to 111In-pentreotide in primary renal cell carcinoma. Nucl Med Commun, 19: 953, 1998
13. Jadvar, H., Kherbache, H. M. and Conti, P. S.: [F-18]-FDG PET in the evaluation of recurrent and metastatic renal cell carcinoma. Presented at annual meeting of the Academy of Molecular Imaging, San Diego, California, October 23-27, 2002
14. Safaei, A., Figlin, R., Hoh, C. K., Silverman, D. H., Seltzer, M., Phelps, M. E. et al: The usefulness of F-18 deoxyglucose wholebody positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol, 57: 56, 2002
15. Wu, H. C., Yen, R. F., Shen, Y. Y., Kao, C. H., Lin, C. C. and Lee, C. C.: Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol, 128: 503, 2002